Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

77 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Sentinel node biopsy in squamous-cell carcinoma of the anal canal.
De Nardi P, Carvello M, Canevari C, Passoni P, Staudacher C. De Nardi P, et al. Among authors: passoni p. Ann Surg Oncol. 2011 Feb;18(2):365-70. doi: 10.1245/s10434-010-1275-x. Epub 2010 Aug 28. Ann Surg Oncol. 2011. PMID: 20803079
Effect on local control and survival of electron beam intraoperative irradiation for resectable pancreatic adenocarcinoma.
Reni M, Panucci MG, Ferreri AJ, Balzano G, Passoni P, Cattaneo GM, Cordio S, Scaglietti U, Zerbi A, Ceresoli GL, Fiorino C, Calandrino R, Staudacher C, Villa E, Di Carlo V. Reni M, et al. Among authors: passoni p. Int J Radiat Oncol Biol Phys. 2001 Jul 1;50(3):651-8. doi: 10.1016/s0360-3016(01)01470-5. Int J Radiat Oncol Biol Phys. 2001. PMID: 11395232 Clinical Trial.
Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial.
Reni M, Cordio S, Milandri C, Passoni P, Bonetto E, Oliani C, Luppi G, Nicoletti R, Galli L, Bordonaro R, Passardi A, Zerbi A, Balzano G, Aldrighetti L, Staudacher C, Villa E, Di Carlo V. Reni M, et al. Among authors: passoni p. Lancet Oncol. 2005 Jun;6(6):369-76. doi: 10.1016/S1470-2045(05)70175-3. Lancet Oncol. 2005. PMID: 15925814 Clinical Trial.
PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) regimen as second-line therapy in patients with progressive or recurrent pancreatic cancer after gemcitabine-containing chemotherapy.
Reni M, Cereda S, Mazza E, Passoni P, Nicoletti R, Balzano G, Zerbi A, Arcidiacono PG, Staudacher C, Di Carlo V. Reni M, et al. Among authors: passoni p. Am J Clin Oncol. 2008 Apr;31(2):145-50. doi: 10.1097/COC.0b013e31814688f7. Am J Clin Oncol. 2008. PMID: 18391598 Clinical Trial.
Adjuvant PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) or gemcitabine followed by chemoradiation in pancreatic cancer: a randomized phase II trial.
Reni M, Balzano G, Aprile G, Cereda S, Passoni P, Zerbi A, Tronconi MC, Milandri C, Saletti P, Rognone A, Fugazza C, Magli A, Di Muzio N, Di Carlo V, Villa E. Reni M, et al. Among authors: passoni p. Ann Surg Oncol. 2012 Jul;19(7):2256-63. doi: 10.1245/s10434-011-2205-2. Epub 2012 Jan 12. Ann Surg Oncol. 2012. PMID: 22237835 Clinical Trial.
77 results